DRUG DELIVERY DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS

• US 20100158980A1
• Filed: 12/18/2008
• Published: 06/24/2010
• Est. Priority Date: 12/18/2008
• Status: Abandoned Application

• Current Assignee: Novaer Holdings, Inc.
• Original Assignee: Novaer Holdings, Inc.
• Inventors: Sutay, Chris, Lin, Cheng-Wen, Kopczynski, Casey
• Application Number:
  US12/337,898
• Publication Number:
  US 20100158980A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Drug delivery devices comprising a non-bioabsorbable polymer structure and a composition comprising an active agent have been discovered. The drug delivery devices may be used to treat ocular conditions, among other diseases and conditions. In addition, a method of treating an ocular condition has been discovered comprising implanting a drug delivery device which releases the active agent at a rate of

Q=0.001×N×C

wherein C is the topical effective concentration (in milligram/mL) of the active agent and N=0.01 to 0.5 for prostaglandins in their ester, amide, free acid or salt form, and N=0.5 to 5 for any active agent other than prostaglandins in their ester, amide, free acid or salt form.

Claims

1. A drug delivery device comprising:

a composition comprising an active agent; and

a non-bioabsorbable polymer structure enclosing the composition, the polymer structure comprising a mixture comprising a water-soluble polymer and a non-water-soluble polymer.

2. The drug delivery device of claim 1, wherein the device at least partially bioerodes when implanted in a body as the water-soluble polymers dissolve leaving a porous structure, through which the active agent is released.

3. The drug delivery device of claim 1, wherein the active agent is an ocular active agent.

4. The drug delivery device of claim 1, wherein the active agent is selected from the group consisting of AR-102, AR-102 free acid, dorzolamide HCl, ethacrynic acid, latanoprost, latanoprost free acid, travoprost, travoprost free acid, bimatoprost, bimatoprost free acid, tafluprost, tafluprost free acid, dexamethasone, brimonidine, timolol, and salts thereof.

5. The drug delivery device of claim 1, wherein the non-water-soluble polymer is selected from the group consisting of EVA-9-50, silicon rubber polymers, polydimethylsiloxane (PDMS), polyurethane (PU), polyesterurethanes, polyetherurethanes, polyolefins, polyethylenes (PE), low density polyethylene (LDPE), polypropylene (PP), polyetheretherketone (PEEK), polysulfone (PSF), polyphenylsulfone, polyacetals, polymethyl methacrylate (PMMA), polybutymethacrylate, plasticized polyethyleneterephthalate, polyisoprene, polyisobutylene, silicon-carbon copolymers, natural rubber, plasticized soft nylon, and polytetrafluoroethylene (PTFE).

6. The drug delivery device of claim 1, wherein the water-soluble polymer is selected from the group consisting of dextran, cyclodextrin, poly-(L-lactic acid), polycaprolactone, poly(lactic-co-glycolic acid), poly(glycolic acid), poly(trimethylene carbonate), and polydioxanone.

7. The drug delivery device of claim 1, wherein the polymer structure has a thickness of about 20 micrometers to about 800 micrometers.

8. The drug delivery device of claim 1, wherein the active agent is released from the drug delivery device at rate of about 0.0001 to about 30 micrograms/hr.

9. The drug delivery device of claim 1, wherein the rate of release of active agent does not substantially deviate from linearity until at least about 70% and at most about 95% of active agent is released from the drug delivery device.

10. The drug delivery device of claim 1, wherein about 70% to about 90% of the active agent is released from the drug delivery device within about 30 days to about 5 years.

38. A method of treating an ocular condition comprising implanting the drug delivery device of claim 1 at or near a tissue affected by the condition.

39. The method of claim 38, wherein the ocular condition is ocular hypertension or glaucoma.

40. The method of claim 38, wherein the drug delivery device is implanted episclerally.

11. A drug delivery device comprising:

a composition comprising an active agent; and

a non-bioabsorbable polymer structure enclosing the composition, the polymer structure comprising an impermeable polymer through which the active agent does not permeate and a partially-bioerodible membrane through which the active agent permeates.

12. The drug delivery device of claim 11, wherein the active agent is an ocular active agent.

13. The drug delivery device of claim 11, wherein the active agent is selected from the group consisting of AR-102, AR-102 free acid, dorzolamide, ethacrynic acid, latanoprost, latanoprost free acid, travoprost, travoprost free acid, bimatoprost, bimatoprost free acid, tafluprost, tafluprost free acid, dexamethasone, brimonidine, timolol, and salts thereof.

14. The drug delivery device of claim 11, wherein the impermeable polymer is selected from the group consisting of EVA-9-50, silicon rubber polymers, polydimethylsiloxane (PDMS), polyurethane (PU), polyesterurethanes, polyetherurethanes, polyolefins, polyethylenes (PE), low density polyethylene (LDPE), polypropylene (PP), polyetheretherketone (PEEK), polysulfone (PSF), polyphenylsulfone, polyacetals, polymethyl methacrylate (PMMA), polybutylmethacrylate, plasticized polyethyleneterephthalate, polyisoprene, polyisobutylene, silicon-carbon copolymers, natural rubber, plasticized soft nylon, and polytetrafluoroethylene (PTFE).

15. The drug delivery device of claim 11, wherein the partially-bioerodible membrane comprises a mixture comprising impermeable polymer and a bioerodible polymer.

16. The drug delivery device of claim 15, wherein the bioerodible polymer is selected from the group consisting of dextran, cyclodextrin, poly-(L-lactic acid), polycaprolactone, poly(lactic-co-glycolic acid), poly(glycolic acid), poly(trimethylene carbonate), and polydioxanone.

17. The drug delivery device of claim 11, wherein the impermeable polymer has a thickness of about 50 micrometers to about 800 micrometers.

18. The drug delivery device of claim 11, wherein the partially-bioerodible membrane has a thickness of about 20 micrometers to about 800 micrometers.

19. The drug delivery device of claim 11, wherein the drug delivery device has a cylindrical structure comprising a cylindrical wall comprising the impermeable polymer and a top comprising the impermeable polymer coupled to the cylindrical wall, and a bottom comprising the partially-bioerodible membrane coupled to the cylindrical wall.

20. The drug delivery device of claim 11, wherein the active agent is released from the drug delivery device at rate of about 0.0001 to about 30 micrograms/hr.

21. The drug delivery device of claim 11, wherein the rate of release of active agent does not substantially deviate from linearity until at least about 70% and at most about 95% of active agent is released from the drug delivery device.

22. The drug delivery device of claim 11, wherein about 70 to about 90% of the active agent is released from the drug delivery device within about 30 days to about 5 years.

41. A method of treating an ocular condition comprising implanting the drug delivery device of claim 11 at or near a tissue affected by the condition.

42. The method of claim 41, wherein the ocular condition is ocular hypertension or glaucoma.

43. The method of claim 41, wherein the drug delivery device is implanted episclerally.

23. A drug delivery device comprising:

a composition comprising a single compressed pellet comprising an active agent with a solubility of greater than about 50 micrograms/mL in phosphate buffered saline at a neutral pH; and

a non-bioabsorbable polymer structure enclosing the composition, the polymer structure comprising an impermeable polymer through which the active agent does not permeate and a rate-limiting water-permeable polymer through which the active agent permeates.

24. The drug delivery device of claim 23, wherein the active agent is an ocular active agent.

25. The drug delivery device of claim 23, wherein the active agent is selected from the group consisting of AR-102, AR-102 free acid, dorzolamide, ethacrynic acid, latanoprost, latanoprost free acid, travoprost, travoprost free acid, bimatoprost, bimatoprost free acid, tafluprost, tafluprost free acid dexamethasone, brimonidine, timolol, and salts thereof.

26. The drug delivery device of claim 23, wherein the impermeable polymer is selected from the group consisting of EVA-9-50, silicon rubber polymers, polydimethylsiloxane (PDMS), polyurethane (PU), polyesterurethanes, polyetherurethanes, polyolefins, polyethylenes (PE), low density polyethylene (LDPE), polypropylene (PP), polyetheretherketone (PEEK), polysulfone (PSF), polyphenylsulfone, polyacetals, polymethyl methacrylate (PMMA), polybutylmethacrylate, plasticized polyethyleneterephthalate, polyisoprene, polyisobutylene, silicon-carbon copolymers, natural rubber, plasticized soft nylon, and polytetrafluoroethylene (PTFE).

27. The drug delivery device of claim 23, wherein the water-permeable polymer is selected from the group consisting of EVA 35-80 and ethylene vinyl alcohol 9-80.

28. The drug delivery device of claim 23, wherein the water-impermeable polymer has a thickness of about 50 micrometers to about 800 micrometers.

29. The drug delivery device of claim 23, wherein the water-permeable polymer has a thickness of about 20 micrometers to about 500 micrometers.

30. The drug delivery device of claim 23, wherein the drug delivery device has a cylindrical structure comprising a cylindrical wall comprising the impermeable polymer and a top comprising the impermeable polymer coupled to the cylindrical wall, and a bottom comprising the partially-bioerodible membrane coupled to the cylindrical wall.

31. The drug delivery device of claim 23, wherein about 5% to about 80% of the active agent is released from the drug delivery device with an R² of at least about 0.95.

32. The drug delivery device of claim 23, wherein the active agent is released from the drug delivery device at rate of about 0.0001 to about 30 micrograms/hr.

33. The drug delivery device of claim 23, wherein the rate of release of active agent does not substantially deviate from linearity until at least about 70% and at most about 95% of active agent is released from the drug delivery device.

34. The drug delivery device of claim 23, wherein about 70 to about 90% of the active agent is released from the drug delivery device within about 30 days to 5 years.

44. A method of treating an ocular condition comprising implanting the drug delivery device of claim 23 at or near a tissue affected by the condition.

45. The method of claim 44, wherein the ocular condition is ocular hypertension or glaucoma.

46. The method of claim 44, wherein the drug delivery device is implanted episclerally.

35. A drug delivery device comprising a composition comprising an active agent at least partially encompassed by an impermeable membrane and a permeable membrane, wherein the permeable membrane controls release of the active agent episclerally over a period of time.

36. The drug delivery device of claim 35, wherein the active agent is an ocular active agent.

37. The drug delivery device of claim 35, wherein the active agent is selected from the group consisting of AR-102, AR-102 free acid, dorzolamide, ethacrynic acid, latanoprost, latanoprost free acid, travoprost, travoprost free acid, bimatoprost, bimatoprost free acid, tafluprost, tafluprost free acid, dexamethasone, brimonidine, timolol, and salts thereof.

47. A method of treating an ocular condition comprising implanting episclerally a drug delivery device comprising an active agent, wherein the active agent is released at a rate of

Q=0.001×

N×

C

wherein C is the topical effective concentration (in milligram/mL) of the active agent and N=0.01 to 0.5 for prostaglandins in their ester, amide, free acid or salt form, and N=0.5 to 5 for any active agent other than prostaglandins in their ester, amide, free acid or salt form.